Product Description
Triamterene is a medication used in the management and treatment of edematous states. It is in the potassium-sparing diuretics class of drugs. This activity outlines the indications, action, and contraindications for triamterene as a valuable agent in managing fluid retaining states and hypertension. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK557650/)
Mechanisms of Action: Sodium Channel Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Bulgaria | Canada | Chile | Colombia | Dominican Republic | Egypt | France | Hong Kong | India | Ireland | Morocco | Netherlands | New Zealand | Pakistan | Peru | Russia | South Africa | Spain | Taiwan | Tunisia | Turkey | United Kingdom | United States | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|